Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer

We studied the added value of digital FDG-PET/CT in disease staging and restaging compared to the standard work-up with contrast enhanced CT (ceCT) and CA19-9 in patients with resectable or borderline resectable pancreatic cancer who received neo-adjuvant therapy. Primary endpoints were tumor respon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Surgical oncology 2023-04, Vol.47, p.101909, Article 101909
Hauptverfasser:	de Jong, Tonke L., Koopman, Daniëlle, van der Worp, Corné A.J., Stevens, Henk, Vuijk, Floris A., Vahrmeijer, Alexander L., Mieog, J. Sven D., de Groot, Jan-Willem B., Meijssen, Maarten A.C., Nieuwenhuijs, Vincent B., de Geus-Oei, Lioe-Fee, Jager, Pieter L., Patijn, Gijs A.
Format:	Artikel
Sprache:	eng
Schlagworte:	CA-19-9 Antigen - therapeutic use Chemoradiotherapy Digital FDG-PET/CT Disease staging Fluorodeoxyglucose F18 FOLFIRINOX Humans LAPC Neo-adjuvant therapy Neoplasm Staging Nuclear medicine Pancreatectomy Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - diagnostic imaging Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - surgery Pancreatic surgery Pancreaticoduodenectomy PDAC Positron Emission Tomography Computed Tomography - methods Positron-Emission Tomography - methods Prospective Studies Radiopharmaceuticals - therapeutic use Retrospective Studies Tumor response evaluation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!